TLX TLX
Company Profile ↓Company Overview
TLX (TLX) is a publicly traded company listed on with a market capitalization of $3.53B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 94.7% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $803.79M (+55.6% YoY); net profit $-7.12M.
- Trailing 12 Months Year-on-year growth — revenue +55.6%, earnings -121.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 94.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 94.69% |
| 1 Year: | 55.61% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -121.15% |
Stock Price Performance
| 1 Year: | -12.95% |
| 6 Months: | +45.94% |
| 3 Months: | -5.62% |
| 1 Month: | -11.24% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)49.36 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 94.7% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 108.91M | 332.98M | 516.55M | 803.79M |
| Cost of Revenue | - | 44.34M | 123.44M | 180.39M | 377.36M |
| Gross Profit | - | 64.58M | 209.53M | 336.16M | 426.44M |
| Operating Expenses | - | 115.05M | 174.57M | 280.58M | 408.38M |
| Operating Income | - | -50.48M | 34.97M | 55.58M | 18.05M |
| EBITDA | - | -62.60M | 11.54M | 62.06M | 35.15M |
| Interest Expense | - | 4.50M | 8.94M | 24.15M | 40.42M |
| Pretax Income | - | -67.09M | 2.59M | 37.91M | -5.27M |
| Tax Provision | - | 3.71M | -1.61M | 4.23M | 1.86M |
| Net Income | - | -70.80M | 4.21M | 33.69M | -7.12M |
| Diluted EPS | - | -0.23 | 0.01 | 0.10 | -0.02 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 173.72M | 277.26M | 940.38M | 1.16B |
| Current Assets | - | 117.85M | 158.69M | 570.12M | 330.28M |
| Cash & Equivalents | - | 79.14M | 84.30M | 440.00M | 141.87M |
| Inventory | - | 5.77M | 12.74M | 23.62M | 37.08M |
| Receivables | - | 26.77M | 44.04M | 86.93M | 129.20M |
| Total Liabilities | - | 119.29M | 174.61M | 587.44M | 748.61M |
| Current Liabilities | - | 58.20M | 111.37M | 205.09M | 231.62M |
| Long Term Debt | - | 2.25M | 5.95M | 341.81M | 391.91M |
| Total Debt | - | 7.11M | 12.26M | 360.16M | 467.11M |
| Total Equity | - | 54.43M | 102.64M | 352.94M | 415.38M |
| Shares Outstanding | - | 316.34M | 323.73M | 334.72M | 338.78M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - |
| Investing Cash Flow | - | -11.56M | -16.84M | -86.69M | -285.92M |
| Financing Cash Flow | - | 119.03M | 7.09M | 416.79M | -3.72M |
| Capital Expenditure | - | -9.43M | -7.11M | -22.18M | -43.78M |
| Free Cash Flow | - | -52.95M | 7.16M | 5.31M | -61.07M |
| Net Change in Cash | - | 63.94M | 4.53M | 357.59M | -306.93M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 59.3% | 62.9% | 65.1% | 53.1% |
| Operating Margin % | - | -46.3% | 10.5% | 10.8% | 2.2% |
| Net Margin % | - | -65.0% | 1.3% | 6.5% | -0.9% |
| ROE % | - | -130.1% | 4.1% | 9.5% | -1.7% |
| ROCE % | - | -43.7% | 21.1% | 7.6% | 1.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TLX
Telix R&D Day to Feature Pipeline Updates and Outside Experts - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPTm9zSzBaSms2a01LR294b3lRTWtJRXVabHZ5T2padWdUSUhjVkc0SFpBMm9ucU5TQ0NkNFJDaXFfVk9EV0VYS2RQSGNuZ19HdTdRSzZMeUo5OUI4eUhoU01ORXpKd3BITlNQLTNZS0laYnIzeUdCclE1cjg4Y19GYjljd1lhVFpfUEFQQ2…
A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Recent Share Price Moves - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPWTh2Y3hwd1VOVXVONlhleVA2YzZROVJYWFJKaUZMcHZ1bVhNYVFFVldoVWptdno2VDluREJrLTlNX0VmbUpCVG5BaWduMzVuT3IzR2hETFhuRTAzRzF1bFRMTm1tdnlhcGJvb3FLaW94d3R1eXFkaUQ5NWFVcm9BY180d25FaW9sbzVFSk…
Telix Stock Price Weakness Could Be Hiding A Growth Story - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxNSVdnRllqLU9hWmp1QnNYUHFwb2JFa0U0S2VVS1FWZVZZMWNjNjMtTVk5QXhDejhlMGxqdU9QdklmM2h0cDYzRTdiay1ycVl2dGd5Z0l0R2l1OW4zT2kyeml0ZTBNUWR4Q3Bsanl0OTk1SndIbi1fQW9IeEhRRUxSSWtqa1lpWERyeUFHWX…
Telix Pharmaceuticals: The Radiopharma Operating System Is The Real Moat (NASDAQ:TLX) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxOQ0tTMF9fbU9RNFZkM0R0ZW1UaEQtejNzUjRFYV95aVZGTXJQdEpLenBsbGt6ZW0xemlQSGFnTkR2ZUR3cVhLSVpsWnAyMlQzdnpINHNVVktJNExRUzFyWmtCUDVuWXZHaS1nWkxBdEN1Z0thcGxVRE82LXJjaElnbnJKMElJMEc4dmFjRm…
Telix Sets August Investor Call for H1 2026 Results - theglobeandmail.com
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxOc2RGZmdSLUthb3ZsSjJSZmQ3ZC04YmlTZXE1Wmd6QzdIdUpOdHZsTFNaVF9pR05mclZOb1pTb0VoaXY1eUFnMDdBa09ORGJsX1dtUF9wYkpOdUJNaHVqNWxjTTZ2RkJqal9ZXzFSSmJGQWw3Ty1hempqMk9wOXpuLVB6NDluWDdaclZWd1…
Telix Pharmaceuticals Limited (TLX) Stock Analysis: Unveiling a 101.56% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxPRWdPSno1QzlQdWc3SzdLTkl6eE1oRUdBa091LWNlZDJhWTQwV0tyRmE2RjZJLUVaUGNRZ3ZDckwzdmVwUzRsREE5LWMydWgtMHh6Y3hac3FhWFYyWC1UYUdfOVhrLU91MjRBUXYybjZqcW92RXlzRmRIYWcyd0YyclJ4dmFldTAyQmZuQU…
TLX — Frequently Asked Questions
What is the current share price of TLX?
As of 2026-08-05 17:25 PDT, TLX trades at $10.42 on NASDAQ/NYSE. Its 52-week range is $6.41 to $12.54.
What is the market capitalisation of TLX?
TLX has a market capitalisation of $3.53B on NASDAQ/NYSE.
What is the P/E ratio of TLX?
TLX trades at a trailing price-to-earnings (P/E) ratio of -493.84. Its price-to-book (P/B) ratio is 8.50.
What is the return on equity (ROE) of TLX?
TLX has a return on equity (ROE) of -1.72%. Its return on capital employed (ROCE) is 1.94%.
Is TLX a good stock to buy?
This page provides a data-driven analysis of TLX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.